Recommended Dose of Envarsus (Tacrolimus Extended-Release)
For de novo kidney transplant recipients, start Envarsus at 0.14 mg/kg/day given once daily, though emerging evidence suggests 0.08-0.12 mg/kg/day may be preferable to avoid early overexposure while maintaining therapeutic efficacy. 1
De Novo Kidney Transplantation
FDA-Approved Starting Dose
The FDA label recommends 0.14 mg/kg/day once daily as the starting dose for de novo kidney transplant recipients 1. However, this recommendation warrants careful consideration based on recent pharmacokinetic data.
Optimized Starting Doses Based on Recent Evidence
The 0.14 mg/kg/day starting dose frequently causes early overexposure. A 2025 study comparing four different starting doses found that:
- 0.08 mg/kg/day achieved the best therapeutic precision, with 41.9% of patients within target range (5-8 ng/mL) at 72 hours
- Only 37.2% had supratherapeutic levels versus 76.9% with 0.15 mg/kg/day
- Required fewer dose holds (14% versus 30.8% with higher doses)
- Maintained equivalent kidney function at 3 months 2
For obese patients (BMI >30 kg/m²), use ideal body weight (IBW) rather than actual body weight for dosing calculations, as IBW correlates more strongly with therapeutic dose requirements (r=0.929). Obese patients require approximately 0.09-0.10 mg/kg/day based on actual weight, which translates to appropriate dosing when IBW is used 3.
Target Trough Concentrations
Maintain tacrolimus trough levels at:
- 6-11 ng/mL during the first month post-transplant
- 4-11 ng/mL thereafter 1
These targets align with EASL 2024 guidelines recommending 6-10 ng/mL in month 1, then 4-8 ng/mL for liver transplantation 4, and are applicable to kidney transplantation.
CYP3A5 Genotype Considerations
CYP3A5 expressers (intermediate and extensive metabolizers) require higher starting doses:
- Start at 0.20 mg/kg/day for CYP3A5 expressers versus 0.13 mg/kg/day for non-expressers
- CYP3A5 expressers take longer to reach therapeutic levels (13.5 days versus 4.5 days)
- They maintain lower mean trough concentrations throughout treatment (7.98 ng/mL versus 10.78 ng/mL) 5
Stable Kidney Transplant Recipients (Conversion from Immediate-Release)
When converting stable patients from tacrolimus immediate-release capsules to Envarsus, use a 1:0.8 ratio (approximately 20-30% dose reduction):
- If on immediate-release tacrolimus 10 mg/day total, start Envarsus at 8 mg once daily
- Monitor trough levels closely and adjust to maintain therapeutic range 1, 6
The 30% dose reduction maintains therapeutic trough concentrations without increasing adverse effects, as demonstrated in conversion studies 6.
Dosing with Concomitant Immunosuppression
When using renal-sparing protocols with basiliximab induction and mycophenolate:
- Target lower tacrolimus trough levels: 4-7 ng/mL during month 1, then 3-5 ng/mL
- This approach preserves renal function without increasing rejection rates 4
The FDA trials used basiliximab induction in 97% of patients with MMF at approximately 1 gram twice daily, supporting this combination approach 1.
Monitoring and Dose Adjustments
Check tacrolimus trough levels:
- Days 2,3,4,7,10,14,21, and 30 post-transplant
- Then at months 2,3,4,6,9, and 12
- Adjust doses in 0.5-1 mg increments to maintain target range 1
Critical timing consideration: Envarsus provides higher early exposure than other once-daily formulations. At 48 hours post-dose, 57.8% of patients on 0.15 mg/kg/day had supratherapeutic levels, with 23.4% requiring temporary discontinuation 7. This reinforces the rationale for lower starting doses (0.08-0.12 mg/kg/day).
Common Pitfalls to Avoid
Don't use actual body weight in obese patients - this leads to overdosing. Use IBW or adjusted body weight 3
Don't maintain the 0.17 mg/kg/day dose used in the pivotal trial - this was acknowledged as approximately 1.2-fold higher than recommended and caused early overexposure 1
Don't assume bioequivalence with immediate-release tacrolimus - Envarsus has 30% higher bioavailability, requiring lower total daily doses 8, 6
For delayed doses: If <12 hours late, take full dose immediately; if 12-24 hours late, take half dose; if completely missed, take 150% at next scheduled time 9